Helicos sets IPO at 5.4 mln shares, $13-$15
WASHINGTON, May 7 (Reuters) - Helicos BioSciences Corp., a genetic analysis technologies firm, set its planned initial public offering on Monday at 5.4 million shares at between $13 and $15 per share.
The underwriters, led by UBS Investment Bank, will have the option to buy another 810,000 shares to cover overallotments, according to an amended offering document filed with the U.S. Securities and Exchange Commission.
The Cambridge, Massachusetts-based company said it is seeking a Nasdaq listing under the symbol "HLCS."
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Quake toll
Almost 10,000 dead in China
